

REQ-2021-050 Supplementary material

Supplementary table 1: Univariate analysis between confirmed and non-confirmed

General features	All patients (n= 1,331)	Confirmed (n= 874)	Suspected (n= 457)	p value
Male*	841 (3.1)	569 (65.1)	272 (59.5)	0.052
Death	233 (17.5%)	168 (19.2)	65 (14.2)	0.028
Age (years)**	66.9 [55.7; 76.8]	67.2 [55.8;76.6]	66.3 [55.6;77.6]	0.905
Age stratified (years)*				
<40	72 (5.4)	48 (5.5)	24 (5.3)	<0.001
40-60	362 (27.2)	240 (27.5)	122 (26.7)	
61-80	661 (49.7)	440 (50.0)	221 (48.4)	
>80	236 (17.3)	146 (16.7)	90 (19.7)	
Length of hospital stayed (days)**	8.00 [6.00; 13.0]	9.00 [6.00;13.0]	7.00 [5.00;11.0]	<0.001
ICU admission*	115 (8.6)	100 (11.4)	15 (3.28)	<0.001
Sign and symptoms at emergency department				
Onset of symptoms to hospital admission (d)	7.00 [3.00; 9.00]	7.00 [3.00;8.00]	7.00 [3.75;10.0]	<0.001
Headache*	16 (1.2)	15 (1.72)	1 (0.22)	0.034
Anosmia*	14 (1.1)	9 (1.03)	5 (1.09)	1.000
Dyspnea*	936 (70.3)	634 (72.5)	302 (66.1)	0.010
Cough *				
No	344 (25.8)	208 (23.8)	136 (29.8)	0.095
Cough + red sputum	5 (0.4)	3 (0.34)	2 (0.44)	
Cough + greenish sputum	8 (0.6)	5 (0.57)	3 (0.66)	
Cough + colourless sputum	69 (5.2)	42 (4.81)	27 (5.91)	
Dry cough	905 (68.0)	616 (70.5)	289 (63.2)	
Fever*	1110 (83.4)	755 (86.4)	355 (77.7)	<0.001
Nausea*	68 (5.1)	47 (5.38)	21 (4.60)	0.628
Diarrhea*	141 (10.6)	84 (9.61)	57 (12.5)	0.129
Systolic blood pressure (mmHg)**	130 [117; 144]	130 [117;143]	134 [119;147]	0.033
Diastolic blood pressure (mmHg)**	76.0 [67.0; 84.0]	76.0 [68.0;83.0]	76.0 [67.0;85.0]	0.409
Heart rate (bpm)**	90.0 [80.0; 102.0]	89.0 [80.0;101]	90.0 [80.0;103]	0.555
Temperature (°C)**	36.7 [36.3; 37.4]	36.8 [36.3;37.4]	36.6 [36.2;37.4]	0.043
Oxygen saturation (%)**	94.0 [90.0; 96.0]	94.0 [91.0;96.0]	93.0 [89.5;95.0]	0.008
Comorbidities				
Number of comorbidities				
0	528 (39.7)	422 (48.3)	243 (53.2)	0.650
1	374 (28.1)	213 (24.4)	102 (22.3)	
2	250 (18.7)	138 (15.8)	65 (14.2)	
3	121 (9.1)	57 (6.5)	29 (6.3)	
4	40 (3.0)	30 (3.4)	15 (3.2)	
5	10 (0.8)	11 (1.2)	2 (0.4)	
6	7 (0.5)	1 (0.1)	0 (0.0)	
7	1 (0.1)	2 (0.02)	1 (0.02)	
Malignancy *	56 (4.2)	44 (5.03)	12 (2.63)	0.053
Diabetes*	167 (12.5)	120 (13.7)	47 (10.3)	0.086
Immunosuppression*	8 (0.6)	4 (0.46)	4 (0.88)	0.457
HIV/AIDS *	1 (0.1)	1 (0.11)	0 (0.00)	1.000
Thyroid disease*	99 (7.4)	61 (6.98)	38 (8.32)	0.440
Dislipemia*	274 (20.6)	192 (22.0)	82 (17.9)	0.098
Smoking*	54 (4.1)	31 (3.55)	23 (5.03)	0.247
Chronic obstructive pulmonary disease*	63 (4.7)	37 (4.23)	26 (5.69)	0.293
Asthma*	52 (3.9)	37 (4.23)	15 (3.28)	0.483
Neurologic disease (Stroke, TIA or dementia) *	52 (3.9)	33 (3.78)	19 (4.16)	0.847
High blood pressure (mmHg)**	500 (37.6)	350 (40.0)	150 (32.8)	0.012
Acute coronary disease*	93 (7.0)	60 (6.86)	33 (7.22)	0.898
Alcohol abuse*	25 (1.9)	18 (2.06)	7 (1.53)	0.645
Chronic kidney disease*	39 (2.9)	26 (2.97)	13 (2.84)	1.000
Chronic liver disease*	14 (1.0)	11 (1.26)	3 (0.66)	0.403
Chronic Medication				
Statins*	233 (17.5)	164 (18.8)	69 (15.1)	0.111
Anticoagulants*	82 (6.2)	63 (7.21)	19 (4.16)	0.038
Antiagregants*	123 (9.2)	87 (9.95)	36 (7.88)	0.253
IECA/ARAII*	328 (24.6)	221 (25.3)	107 (23.4)	0.493
Beta blockers*	150 (11.3)	99 (11.3)	51 (11.2)	1.000
Diuretics*	103 (7.7)	37 (4.23)	66 (14.4)	<0.001
Thyroid replacement hormones*	96 (7.2)	63 (7.21)	33 (7.22)	1.000
Oral steroids*	21 (1.6)	15 (1.72)	6 (1.31)	0.597
Inhaled steroids*	48 (3.6)	29 (3.32)	19 (4.16)	0.438
Inhaled b2 agonist*	33 (2.5)	19 (2.17)	14 (3.4)	0.329
Inhaled antimuscarinic*	30 (2.3)	18 (2.06)	12 (2.63)	0.540

Supplementary table 1: Univariate analysis between confirmed and non-confirmed (cont.)

Laboratory findings at emergency department	All patients (n= 1331)	Confirmed (n= 874)	Suspected (n= 457)	p value
Hemoglobine (g/dL) **	14.1 [13.1;15.2]	14.1 [13.1;15.2]	14.1 [13.0;15.1]	0.370
White Blood cell (count x10 ⁹ /L) **	6.33 [4.91;8.51]	6.09 [4.71;8.24]	6.88 [5.35;9.11]	<0.001
Neutrophil (count x10 ⁹ /L) **	4.69 [3.33;6.81]	4.50 [3.18;6.51]	5.19 [3.69;7.32]	<0.001
Lymphocyte (count x10 ⁹ /L) **	1.00 [0.71;1.35]	0.98 [0.67;1.30]	1.02 [0.75;1.44]	0.007
Monocyte (count x10 ⁹ /L) **	0.45 [0.32;0.63]	0.44 [0.31;0.61]	0.49 [0.34;0.68]	0.001
Basofiles (count x10 ⁹ /L) **	0.01 [0.01;0.02]	0.01 [0.01;0.02]	0.02 [0.01;0.03]	<0.001
Eosinophil (count x10 ⁹ /L) **	0.00 [0.00;0.02]	0.00 [0.00;0.02]	0.01 [0.00;0.03]	<0.001
Platelet (count x10 ⁹ /L) **	192 [154;245]	182 [148;231]	214 [169;279]	<0.001
Glucose (mg/dl) **	116 [104;136]	116 [103;137]	115 [104;136]	0.850
Prothrombine activity (%) **	76.0 [68.0;85.0]	78.0 [69.0;86.0]	74.0 [67.0;83.0]	0.001
Activated partial thromboplastin time (s) **	32.2 [30.0;34.8]	32.4 [30.2;35.1]	31.5 [29.8;33.9]	0.002
Total bilirubine (mg/dl) **	0.46 [0.34;0.62]	0.46 [0.33;0.64]	0.45 [0.34;0.60]	0.405
Aspartate aminotransferase (U/L) **	36.0 [26.0;55.8]	36.4 [26.3;55.8]	34.7 [25.0;55.9]	0.319
Alanine aminotransferase (U/L) **	28.4 [18.0;46.0]	28.4 [18.0;46.2]	28.5 [18.5;44.7]	0.435
International normalized ratio **	1.19 [1.11;1.30]	1.19 [1.10;1.29]	1.21 [1.13;1.32]	0.017
D dimer (mg/L) **	724 [448;1178]	692 [430;1096]	765 [501;1323]	0.010
Lactate dehydrogenase (U/L) **	554 [430;714]	548 [419;704]	560 [446;725]	0.116
Sodium (mmol/L) **	136 [134;139]	136 [134;138]	137 [135;139]	<0.001
Potassium (mmol/L) **	4.17 [3.87;4.50]	4.16 [3.86;4.49]	4.19 [3.90;4.52]	0.478
C reactive protein (mg/dl) **	79.1 [33.9;152]	74.5 [32.2;147]	91.0 [39.4;158]	0.047
Blood urea nitrogen (mg/dl) **	32.7 [25.0;45.8]	33.3 [25.3;46.0]	31.0 [24.4;45.5]	0.261
Creatinine (mg/dL) **	0.92 [0.74;1.09]	0.93 [0.76;1.11]	0.88 [0.71;1.04]	0.003
Pharmacological treatments during hospitalization				
Tocilizumab**				
No	1010 (75.9)	660 (75.5)	350 (76.6)	<0.001
0-599mg	80 (6.0)	62(7.1)	18(3.9)	
600-999mg	213 (16.0)	126 (14.4)	87(19)	
>=1000mg	28 (2.1)	26(3)	2(0.5)	
Steroids*				
No	708 (53.2)	475 (54.4)	233 (51)	
0-49 mg/day	144 (10.8)	107 (12.2)	37(8.1)	
50-99 mg /day	231 (17.3)	145(16.6)	86(18.8)	
>=100 mg/day	248 (18.6)	147(16.8)	101(22.1)	
Steroids bolus	249 (18.7)	151 (17,3)	98 (21,4)	0.076
Hydroxychloroquine*	1197 (89.9)	792 (77.2)	405 (92.8)	0.292
Lopinavir/ritonavir*	956 (71,8)	654 (63.1)	302 (73.6)	<0.001
Cytostatic*	28 (2.1)	25 (2.9)	3 (0.7)	0.013
Colchicine*	38 (2.8)	25 (2.9)	13 (2.8)	0.875
Polyclonal immunoglobulins*	13 (1.0)	11 (1.3)	2 (0.4)	0.249
Montelukast*	78 (5.9)	52 (5.9)	26 (5.7)	0.945
Ascorbic acid*	30 (2.3)	17 (1.9)	13 (2.8)	0.392
HMG-CoA*	144 (10.8)	108 (12.4)	36 (7.9)	0.016

Supplementary figure 1: Survivor analysis of pharmacological interventions according to the moment of administration (early vs later)

